Cargando…
Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859938/ https://www.ncbi.nlm.nih.gov/pubmed/24157831 http://dx.doi.org/10.1038/bjc.2013.651 |
| _version_ | 1782295473818697728 |
|---|---|
| author | Bibeau, F Gil, H Castan, F Boissière-Michot, F |
| author_facet | Bibeau, F Gil, H Castan, F Boissière-Michot, F |
| author_sort | Bibeau, F |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3859938 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-38599382013-12-12 Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' Bibeau, F Gil, H Castan, F Boissière-Michot, F Br J Cancer Letter to the Editor Nature Publishing Group 2013-12-10 2013-10-24 /pmc/articles/PMC3859938/ /pubmed/24157831 http://dx.doi.org/10.1038/bjc.2013.651 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
| spellingShingle | Letter to the Editor Bibeau, F Gil, H Castan, F Boissière-Michot, F Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' |
| title | Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' |
| title_full | Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' |
| title_fullStr | Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' |
| title_full_unstemmed | Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' |
| title_short | Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab' |
| title_sort | comment on ‘histopathologic evaluation of liver metastases from colorectal cancer in patients treated with folfoxiri plus bevacizumab' |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859938/ https://www.ncbi.nlm.nih.gov/pubmed/24157831 http://dx.doi.org/10.1038/bjc.2013.651 |
| work_keys_str_mv | AT bibeauf commentonhistopathologicevaluationoflivermetastasesfromcolorectalcancerinpatientstreatedwithfolfoxiriplusbevacizumab AT gilh commentonhistopathologicevaluationoflivermetastasesfromcolorectalcancerinpatientstreatedwithfolfoxiriplusbevacizumab AT castanf commentonhistopathologicevaluationoflivermetastasesfromcolorectalcancerinpatientstreatedwithfolfoxiriplusbevacizumab AT boissieremichotf commentonhistopathologicevaluationoflivermetastasesfromcolorectalcancerinpatientstreatedwithfolfoxiriplusbevacizumab |